The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study

Basit Öğe Kaydı
dc.authorideser, fatma/0000-0002-0282-6346
dc.authoridAkdag, Damla/0000-0003-1700-7578
dc.authoridBERK, HANDE/0000-0002-2820-1731
dc.contributor.authorElik, Dilsah Baskol
dc.contributor.authorKaya, Safak
dc.contributor.authorAlkan, Sevil
dc.contributor.authorDemirdal, Tuna
dc.contributor.authorSener, Alper
dc.contributor.authorKaya, Selcuk
dc.contributor.authorTunccan, Ozlem Guzel
dc.date.accessioned2025-01-27T20:23:09Z
dc.date.available2025-01-27T20:23:09Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThis multicentre (22 centres in Turkey) retrospective cohort study aimed to assess the clinical outcomes of patients with neutropenic fever and SARS-CoV-2 positivity. Study period was 15 March 2020-15 August 2021. A total of 170 cases (58 female, aged 59 +/- 15.5 years) that fulfilled the inclusion criteria were included in the study. One-month mortality rate (OMM) was 44.8%. The logistic regression analysis showed the following significant variables for the mentioned dependent variables: (i) achieving PCR negativity: receiving a maximum of 5 days of favipiravir (p = 0.005, OR 5.166, 95% CI 1.639-16.280); (ii) need for ICU: receiving glycopeptide therapy at any time during the COVID-19/FEN episode (p = 0.001, OR 6.566, 95% CI 2.137-20.172), the need for mechanical ventilation (p < 0.001, OR 62.042, 95% CI 9.528-404.011); (iii) need for mechanical ventilation: failure to recover from neutropenia (p < 0.001, OR 17.869, 95% CI 3.592-88.907), receiving tocilizumab therapy (p = 0.028, OR 32.227, 95% CI 1.469-707.053), septic shock (p = 0.001, OR 15.4 96% CI 3.164-75.897), and the need for ICU (p < 0.001, OR 91.818, 95% CI 15.360-548.873), (iv) OMM: [mechanical ventilation (p = 0.001, OR 19.041, 95% CI 3.229-112.286) and septic shock (p = 0.010, OR 5.589,95% CI 1.509-20.700)]. Although it includes a relatively limited number of patients, our findings suggest that COVID-19 and FEN are associated with significant mortality and morbidity.
dc.identifier.doi10.1038/s41598-024-55886-w
dc.identifier.issn2045-2322
dc.identifier.issue1
dc.identifier.pmid38433274
dc.identifier.scopus2-s2.0-85186610412
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1038/s41598-024-55886-w
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22134
dc.identifier.volume14
dc.identifier.wosWOS:001184650000016
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherNature Portfolio
dc.relation.ispartofScientific Reports
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectCovid-19
dc.subjectCancer
dc.subjectSeverity
dc.titleThe clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu